The new results from the retrospective validation study of the DAWN IO Melanoma test in 205 patients with advanced melanoma. The study was conducted in collaboration with MGH
The results demonstrated a glycoproteomic biomarker signature in MM patients as likely or not to benefit from ICIs while the unlikely to benefit group showed an m-PFS of 2.5mos. vs 17.34mos. for the likely to benefit group, 12% of patients were unlikely to respond while 10% were classified as indeterminate
InterVenn is starting the recruitment for HELIOS-001 to support further development of DAWN in patients with advanced malignancies who will begin ICI treatment. CLIA allows InterVenn’s clinical laboratory to do high-complexity tests
Ref: Businesswire | Image: InterVenn
